title: Reduced efficacy of intermittent preventive treatment of malaria in malnourished children.
abstract: Intermittent preventive treatment in infants with sulfadoxine-pyrimethamine (IPTi-SP) reduces malaria episodes by 20 to 59% across Africa. This protective efficacy, however, may be affected by the high frequency of malnutrition in African infants. We analyzed the impact of malnutrition as defined by anthropometry on the incidence of malaria and on the protective efficacy of IPTi in a cohort of 1,200 children in northern Ghana, where malaria is hyperendemic. These children received IPTi-SP or placebo at 3, 9, and 15 months of age and were monitored until 24 months of age. Malnutrition was present in 32, 40, and 50% of children at ages 3, 9, and 15 months, respectively. It was associated with increased risks of severe anemia and death but not an increased risk of malaria. Although malaria slightly contributed to chronic malnutrition, IPTi did not substantially improve child growth. Importantly, the protective efficacies of IPTi in malnourished children were roughly half or even less of those observed in nonmalnourished children. In the first year of life, IPTi reduced the incidence of malaria to a significantly lesser extent in infants who received both doses in a malnourished condition (25%; 95% confidence interval [CI], -7 to 48%) compared to that of nonmalnourished children (46%; 95% CI, 30 to 58%; P = 0.049). Moreover, in contrast to nutritionally advantaged children, the rate of severe malaria appeared to be increased in malnourished children who took IPTi. IPTi might exhibit reduced efficacy in regions of abundant malnutrition. Concomitant nutrition programs may be needed in these places to achieve the desired impact.
authors.affiliation: Institute of Tropical Medicine and International Health, Charité University Medicine, Berlin, Germany.
authors.forename: Ina
authors.initials: I
authors.lastname: Danquah
authors.forename: Ekkehart
authors.initials: E
authors.lastname: Dietz
authors.forename: Philipp
authors.initials: P
authors.lastname: Zanger
authors.forename: Klaus
authors.initials: K
authors.lastname: Reither
authors.forename: Peter
authors.initials: P
authors.lastname: Ziniel
authors.forename: Ulrich
authors.initials: U
authors.lastname: Bienzle
authors.forename: Frank P
authors.initials: FP
authors.lastname: Mockenhaupt
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005869:Ghana / Q000453:epidemiology; D006801:Humans; D007223:Infant; D017053:Infection Control / Q000379:methods*; D008288:Malaria / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D044342:Malnutrition / Q000150:complications* / Q000453:epidemiology; D009752:Nutritional Status; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine